Metabolomic fingerprinting: Challenges and opportunities

Critical Reviews in Biomedical Engineering

Volumn 41, Issue 3, 2013, Pages 205-221

  Kosmides, Alyssa K ^a   Kamisoglu, Kubra ^b   Calvano, Steve E ^c   Corbett, Siobhan A ^c   Androulakis, Ioannis P ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b The State University of New Jersey   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Bioinformatics; Data analysis; Disease modeling; Metabolomics

Indexed keywords

DATA COLLECTION METHOD; DISEASE MODELING; DYNAMIC INTERACTION; IN-DEPTH UNDERSTANDING; INTEGRATED APPROACH; METABOLIC PROFILES; METABOLOMICS; MULTIVARIATE ANALYSIS TECHNIQUES;

BIOINFORMATICS; DATA REDUCTION; METABOLITES; MOLECULAR BIOLOGY; TISSUE;

DIAGNOSIS;

ARTICLE; DATA COLLECTION METHOD; GENOMICS; HUMAN; METABOLITE; METABOLOMICS; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SYSTEMS BIOLOGY; TISSUE SPECIFICITY; TOXICITY TESTING; TRANSCRIPTOMICS;

ALGORITHMS; ANIMALS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; CORONARY DISEASE; CRITICAL ILLNESS; CYTOKINES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; NEOPLASMS; OBESITY; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; SOFTWARE; SYSTEMS BIOLOGY; TOXICITY TESTS;

EID: 84896896691     PISSN: 0278940X     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevBiomedEng.2013007736     Document Type: Article

References (103)

1. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol. 2006;2:52.
2. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134(5):714-7.
3. Nicholson JK, Holmes E, Lindon JC, Wilson ID. The challenges of modeling mammalian biocomplexity. Nat Biotechnol. 2004;22(10):1268-74.
4. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, Daviglus ML, Kesteloot H, Ueshima H, Zhao L, Nicholson JK, Elliott P. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453(7193):396-400.
5. Nicholson JK, Wilson ID. Opinion: understanding "global" systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003;2(8):668-76.
6. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther. 2010;88(1):45-51.
7. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455(7216):1054-6.
8. Chemometrics. Multivariate solutions to metabonomic profiling and functional genomics, part 2 [2 Sept 2006; cited 23 Nov 2013]. Available at: http://chemometrics. se/2006/09/02/multivariate-solutions-to-metabonomicprofilingand-functional-genomics-part-2/.
9. Kölsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, Kornhuber J, Frölich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den Bussche H, Hüll M, Kurz A, Rüther E, Henn FA, Maier W. Association of SORL1 gene variants with Alzheimer's disease. Brain Res. 2009;1264:1-6.
10. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603.
11. Hinkelbein J, Feldmann RE Jr, Peterka A, Schubert C, Schelshorn D, Maurer MH, Kalenka A. Alterations in cerebral metabolomics and proteomic expression during sepsis. Curr Neurovasc Res. 2007;4(4):280-8.
12. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181-9.
13. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512-9.
14. Kinross JM, von Roon AC, Holmes E, Darzi A, Nicholson JK. The human gut microbiome: implications for future health care. Curr Gastroenterol Rep. 2008;10(4):396-403.
15. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-8.
16. Kinross J, von Roon AC, Penney N, Holmes E, Silk D, Nicholson JK, Darzi A. The gut microbiota as a target for improved surgical outcome and improved patient care. Curr Pharm Des. 2009;15(13):1537-45.
17. Calvani R, Miccheli A, Capuani G, Tomassini Miccheli A, Puccetti C, Delfini M, Iaconelli A, Nanni G, Mingrone G. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int J Obes (Lond). 2010;34(6):1095-8.
18. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao L. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008;105(6):2117-22.
19. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-31.
20. Williams RE, Lenz EM, Evans JA, Wilson ID, Granger JH, Plumb RS, Stumpf CL. A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J Pharm Biomed Anal. 2005;38(3):465-71.
21. MacFie J, O'Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut. 1999;45(2):223-8.
22. Shimizu K, Ogura H, Goto M, Asahara T, Nomoto K, Morotomi M, Yoshiya K, Matsushima A, Sumi Y, Kuwagata Y, Tanaka H, Shimazu T, Sugimoto H. Altered gut flora and environment in patients with severe SIRS. J Trauma. 2006;60(1):126-33.
23. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005;3(5):431-8.
24. Callinan PA, Feinberg AP. The emerging science of epigenomics. Hum Mol Genet. 2006;15 Spec No 1:R95-101.
25. Bonetta L. Epigenomics: the new tool in studying complex diseases. Nat Educ. 2008;1(1):178.
26. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8(4):253-62.
27. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457-63.
28. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1(2):153-61.
29. Griffin JL, Bollard ME. Metabonomics: its potential as a tool in toxicology for safety assessment and data integration. Curr Drug Metab. 2004;5(5):389-98.
30. Maher AD, Zirah SF, Holmes E, Nicholson JK. Experimental and analytical variation in human urine in 1H NMR spectroscopy-based metabolic phenotyping studies. Anal Chem. 2007;79(14):5204-11.
31. Keun HC, Ebbels TM, Antti H, Bollard ME, Beckonert O, Schlotterbeck G, Senn H, Niederhauser U, Holmes E, Lindon JC, Nicholson JK. Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. Chem Res Toxicol. 2002;15(11):1380-6.
32. Lin C, Wu H, Tjeerdema R, Viant M. Evaluation of metabolite extraction strategies from tissue samples using NMR metabolomics. Metabolomics. 2007;3(1):55-67.
33. Lindon JC, Nicholson JK, Holmes E, Everett JR. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson. 2000;12(5):289-320.
34. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2(11):2692-703.
35. Beckwith-Hall BM, Nicholson JK, Nicholls AW, Foxall PJ, Lindon JC, Connor SC, Abdi M, Connelly J, Holmes E. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol. 1998;11(4):260-72.
36. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910-4.
37. Kell DB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol. 2004;7(3): 296-307.
38. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res. 2007;6(2):443-58.
39. Reo NV. NMR-based metabolomics. Drug Chem Toxicol. 2002;25(4):375-82.
40. Keun HC, Beckonert O, Griffin JL, Richter C, Moskau D, Lindon JC, Nicholson JK. Cryogenic probe 13C NMR spectroscopy of urine for metabonomic studies. Anal Chem. 2002;74(17):4588-93.
41. Lu X, Zhao X, Bai C, Zhao C, Lu G, Xu G. LC-MS-based metabonomics analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;866(1-2):64-76.
42. O'Hagan S, Dunn WB, Knowles JD, Broadhurst D, Williams R, Ashworth JJ, Cameron M, Kell DB. Closed-loop, multiobjective optimization of two-dimensional gas chromatography/ mass spectrometry for serum metabolomics. Anal Chem. 2007;79(2):464-76.
43. An Z, Chen Y, Zhang R, Song Y, Sun J, He J, Bai J, Dong L, Zhan Q, Abliz Z. Integrated ionization approach for RRLCMS/ MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res. 2010;9(8):4071-81.
44. Rooney OM, Troke J, Nicholson JK, Griffin JL. High-resolution diffusion and relaxation-edited magic angle spinning 1H NMR spectroscopy of intact liver tissue. Magn Reson Med. 2003;50(5):925-30.
45. Griffin JL, Troke J, Walker LA, Shore RF, Lindon JC, Nicholson JK. The biochemical profile of rat testicular tissue as measured by magic angle spinning 1H NMR spectroscopy. FEBS Lett. 2000;486(3):225-9.
46. Coen M, Kuchel PW. Metabonomics based on NMR spectroscopy. Chem Aust. 2004;71(6):13-17.
47. Griffin JL. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci. 2006;361(1465):147-61.
48. Cui Q, Lewis IA, Hegeman AD, Anderson ME, Li J, Schulte CF, Westler WM, Eghbalnia HR, Sussman MR, Markley JL. Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol. 2008;26(2):162-4.
49. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007;35(Database issue):D521-6.
50. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009;37(Web Server issue):W652-60.
51. Xia J, Bjorndahl TC, Tang P, Wishart DS. MetaboMinersemi-automated identification of metabolites from 2D NMR spectra of complex biofluids. BMC Bioinformatics. 2008;9:507.
52. Cloarec O, Dumas ME, Craig A, Barton RH, Trygg J, Hudson J, Blancher C, Gauguier D, Lindon JC, Holmes E, Nicholson J. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem. 2005;77(5):1282-9.
53. Keun HC, Ebbels TM, Bollard ME, Beckonert O, Antti H, Holmes E, Lindon JC, Nicholson JK. Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chem Res Toxicol. 2004;17(5):579-87.
54. Azmi J, Griffin JL, Antti H, Shore RF, Johansson E, Nicholson JK, Holmes E. Metabolic trajectory characterisation of xenobiotic-induced hepatotoxic lesions using statistical batch processing of NMR data. Analyst. 2002;127(2):271-6.
55. Torgrip RJO, Åberg M, Karlberg B, Jacobsson S. Peak alignment using reduced set mapping. J Chemom. 2003;17(11):573-82.
56. Cloarec O, Dumas ME, Trygg J, Craig A, Barton RH, Lindon JC, Nicholson JK, Holmes E. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal Chem. 2005;77(2):517-26.
57. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom. 2006;20(8-10):341-51.
58. Mao H, Wang H, Wang B, Liu X, Gao H, Xu M, Zhao H, Deng X, Lin D. Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach. J Proteome Res. 2009;8(12):5423-30.
59. Gavaghan CL, Wilson ID, Nicholson JK. Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLSDA. FEBS Lett. 2002;530(1-3):191-6.
60. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1HNMR-based metabonomics. Nat Med. 2002;8(12):1439-44.
61. Holmes E, Bonner FW, Sweatman BC, Lindon JC, Beddell CR, Rahr E, Nicholson JK. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine. Mol Pharmacol. 1992;42(5):922-30.
62. Veselkov KA, Pahomov VI, Lindon JC, Volynkin VS, Crockford D, Osipenko GS, Davies DB, Barton RH, Bang JW, Holmes E, Nicholson JK. A metabolic entropy approach for measurements of systemic metabolic disruptions in patho-physiological states. J Proteome Res. 2010;9(7):3537-44.
63. Cavill R, Keun HC, Holmes E, Lindon JC, Nicholson JK, Ebbels TM. Genetic algorithms for simultaneous variable and sample selection in metabonomics. Bioinformatics. 2009;25(1):112-8.
64. Li Z, Srivastava S, Mittal S, Yang X, Sheng L, Chan C. A Three Stage Integrative Pathway Search (TIPS) framework to identify toxicity relevant genes and pathways. BMC Bioinformatics. 2007;8:202.
65. Neuweger H, Albaum SP, Dondrup M, Persicke M, Watt T, Niehaus K, Stoye J, Goesmann A. MeltDB: a software platform for the analysis and integration of metabolomics experiment data. Bioinformatics. 2008;24(23):2726-32.
66. Xia J, Wishart DS. MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res. 2010;38(Suppl):W71-7.
67. Suhre K, Schmitt-Kopplin P. MassTRIX: mass translator into pathways. Nucleic Acids Res. 2008;36(Web Server issue):W481-4.
68. Izquierdo-Garcia JL, Rodriguez I, Kyriazis A, Villa P, Barreiro P, Desco M, Ruiz-Cabello J. A novel R-package graphic user interface for the analysis of metabonomic profiles. BMC Bioinformatics. 2009;10:363.
69. Zhao Q, Stoyanova R, Du S, Sajda P, Brown TR. HiResa tool for comprehensive assessment and interpretation of metabolomic data. Bioinformatics. 2006;22(20):2562-4.
70. Antonov AV, Dietmann S, Wong P, Mewes HW. TICL-a web tool for network-based interpretation of compound lists inferred by high-throughput metabolomics. FEBS J. 2009;276(7):2084-94.
71. Lindon J, Keun H, Ebbels T, Pearce J, Holmes E, Nicholson J. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics. 2005;6(7):691-9.
72. Zuppi C, Messana I, Forni F, Rossi C, Pennacchietti L, Ferrari F, Giardina B. 1H NMR spectra of normal urines: reference ranges of the major metabolites. Clin Chim Acta. 1997;265(1):85-97.
73. Shockcor JP, Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem. 2002;2(1):35-51.
74. Smith LM, Maher AD, Want EJ, Elliott P, Stamler J, Hawkes GE, Holmes E, Lindon JC, Nicholson JK. Large-scale human metabolic phenotyping and molecular epidemiological studies via 1H NMR spectroscopy of urine: investigation of borate preservation. Anal Chem. 2009;81(12):4847-56.
75. Bollard ME, Holmes E, Lindon JC, Mitchell SC, Branstetter D, Zhang W, Nicholson JK. Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution (1)H NMR spectroscopy of urine and pattern recognition. Anal Biochem. 2001;295(2):194-202.
76. Slupsky CM, Rankin KN, Wagner J, Fu H, Chang D, Weljie AM, Saude EJ, Lix B, Adamko DJ, Shah S, Greiner R, Sykes BD, Marrie TJ. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem. 2007;79(18):6995-7004.
77. Psihogios NG, Gazi IF, Elisaf MS, Seferiadis KI, Bairaktari ET. Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed. 2008;21(3):195-207.
78. Gu H, Pan Z, Xi B, Hainline BE, Shanaiah N, Asiago V, Gowda GA, Raftery D. 1H NMR metabolomics study of age profiling in children. NMR Biomed. 2009;22(8):826-33.
79. Gavaghan McKee CL, Wilson ID, Nicholson JK. Metabolic phenotyping of nude and normal (Alpk:ApfCD, C57BL10J) mice. J Proteome Res. 2006;5(2):378-84.
80. Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, Lindon JC, Nicholson JK. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc. 2010;5(6):1019-32.
81. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440(7087):1073-7.
82. Anthony ML, Sweatman BC, Beddell CR, Lindon JC, Nicholson JK. Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine. Mol Pharmacol. 1994;46(1):199-211.
83. Gartland KP, Bonner FW, Nicholson JK. Investigations into the biochemical effects of region-specific nephrotoxins. Mol Pharmacol. 1989;35(2):242-50.
84. Holmes E, Nicholls AW, Lindon JC, Ramos S, Spraul M, Neidig P, Connor SC, Connelly J, Damment SJ, Haselden J, Nicholson JK. Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed. 1998;11(4-5):235-44.
85. Aller MA, Arias JI, Alonso-Poza A, Arias J. A review of metabolic staging in severely injured patients. Scand J Trauma Resusc Emerg Med.18(1):27.
86. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, Keun HC. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2009;8(1):352-61.
87. Fan X, Bai J, Shen P. Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods. Conf Proc IEEE Eng Med Biol Soc. 2005;6:6081-4.
88. Frickenschmidt A, Frohlich H, Bullinger D, Zell A, Laufer S, Gleiter CH, Liebich H, Kammerer B. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers. 2008;13(4):435-49.
89. Keun HC, Sidhu J, Pchejetski D, Lewis JS, Marconell H, Patterson M, Bloom SR, Amber V, Coombes RC, Stebbing J. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin Cancer Res. 2009;15(21):6716-23.
90. Markuszewski MJ, Struck W, Waszczuk-Jankowska M, Kaliszan R. Metabolomic approach for determination of urinary nucleosides as potential tumor markers using electromigration techniques. Electrophoresis. 2010;31(14):2300-10.
91. Saric J, Li JV, Swann JR, Utzinger J, Calvert G, Nicholson JK, Dirnhofer S, Dallman MJ, Bictash M, Holmes E. Integrated cytokine and metabolic analysis of pathological responses to parasite exposure in rodents. J Proteome Res. 2010;9(5):2255-64.
92. Yang R, Han X, Uchiyama T, Watkins SK, Yaguchi A, Delude RL, Fink MP. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol. 2003;285(3):G621-9.
93. Guo W, Magnotti LJ, Ding J, Huang Q, Xu D, Deitch EA. Influence of gut microflora on mesenteric lymph cytokine production in rats with hemorrhagic shock. J Trauma. 2002;52(6):1178-85; discussion 85.
94. Yizhak K, Benyamini T, Liebermeister W, Ruppin E, Shlomi T. Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics. 2010;26(12):i255-60.
95. Griffin JL, Bonney SA, Mann C, Hebbachi AM, Gibbons GF, Nicholson JK, Shoulders CC, Scott J. An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol Genomics. 2004;17(2):140-9.
96. Kochhar S, Jacobs DM, Ramadan Z, Berruex F, Fuerholz A, Fay LB. Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal Biochem. 2006;352(2):274-81.
97. Gu H, Chen H, Pan Z, Jackson AU, Talaty N, Xi B, Kissinger C, Duda C, Mann D, Raftery D, Cooks RG. Monitoring diet effects via biofluids and their implications for metabolomics studies. Anal Chem. 2007;79(1):89-97.
98. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 2005;18(3):143-62.
99. Sangster TP, Wingate JE, Burton L, Teichert F, Wilson ID. Investigation of analytical variation in metabonomic analysis using liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(18):2965-70.
100. Ma S, Chowdhury SK, Alton KB. Application of mass spectrometry for metabolite identification. Curr Drug Metab. 2006;7(5):503-23.
101. Dear GJ, Ayrton J, Plumb R, Sweatman BC, Ismail IM, Fraser IJ, Mutch PJ. A rapid and efficient approach to metabolite identification using nuclear magnetic resonance spectroscopy, liquid chromatography/mass spectrometry and liquid chromatography/nuclear magnetic resonance spectroscopy/sequential mass spectrometry. Rapid Commun Mass Spectrom. 1998;12(24):2023-30.
102. Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics. 2007;8(9):1243-66. 103.
103. Kraly JR, Holcomb RE, Guan Q, Henry CS. Review: microfluidic applications in metabolomics and metabolic profiling. Anal Chim Acta. 2009;653(1):23-35.